ITGA2B and acute coronary syndrome: It recognizes the Arg-Gly-Asp sequence in the β3 subunit of the receptor, ultimately leading to the inhibition of blood clot formation.[6] GP IIb/IIIa antagonists are commonly used in patients with acute coronary syndromes and those undergoing coronary stent implantation.